ReviewMolecular neurobiology2018
MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis.
Review in Molecular neurobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- A Machine Learning Approach for Highlighting microRNAs as Biomarkers Linked to Amyotrophic Lateral Sclerosis Diagnosis and Progression.Biomolecules · 2023Pooled it
- Identification of let-7f and miR-338 as plasma-based biomarkers for sporadic amyotrophic lateral sclerosis using meta-analysis and empirical validation.Scientific reports · 2022Pooled it
- The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis.Journal of molecular neuroscience : MN · 2018Pooled it
- Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.JAMA neurology · 2026Trial
- miRNAs in Amyotrophic Lateral Sclerosis: Tiny Molecules, Tremendous Impact.Molecular neurobiology · 2026Review
- Preservation of miR-9-5p and miR-124-3p in ALS-resistant oculomotor neurons contrasts with their downregulation in vulnerable spinal motor neurons, irrespective of TDP-43 pathology.Acta neuropathologica · 2026Article
- Evaluation of Inspiratory Muscle Training Effect Compared With Diaphragmatic Breathing in Respiratory Parameters in Amyotrophic Lateral Sclerosis Patients: A Randomized Controlled Trial.Medical journal of the Islamic Republic of Iran · 2025Article
- Multiomic ALS signatures highlight subclusters and sex differences suggesting the MAPK pathway as therapeutic target.Nature communications · 2024Article
- Differential Expression of miRNAs in Amyotrophic Lateral Sclerosis Patients.Molecular neurobiology · 2023Article
- Multidimensional biomarkers for multiple system atrophy: an update and future directions.Translational neurodegeneration · 2023Review
- Review
- miRNA analysis reveals novel dysregulated pathways in amyotrophic lateral sclerosis.Human molecular genetics · 2023Article
- Implications of miRNAs dysregulation in amyotrophic lateral sclerosis: Challenging for clinical applications.Frontiers in neuroscience · 2023Review
- Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases.Journal of personalized medicine · 2022Review
- Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes.Cellular and molecular life sciences : CMLS · 2022Article
- Exosomal noncoding RNAs in central nervous system diseases: biological functions and potential clinical applications.Frontiers in molecular neuroscience · 2022Review
- Analysis of miRNA rare variants in amyotrophic lateral sclerosis andFrontiers in genetics · 2022Article
- Systems Biology to Address Unmet Medical Needs in Neurological Disorders.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice.PloS one · 2022Article
- RNA Modifications and RNA Metabolism in Neurological Disease Pathogenesis.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are a subset of endogenous, small, non-coding RNA molecules involved in the post-transcriptional regulation of eukaryotic gene expression. Dysregulation in miRNA-related pathways in the central nervous system (CNS) is associated with severe neuronal injury and cell death, which can lead to the development of neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS). ALS is a fatal adult onset disease characterized by the selective loss of upper and lower motor neurons. While the pathogenesis of ALS is still largely unknown, familial ALS forms linked to TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS) gene mutations, as well as sporadic forms, display changes in several steps of RNA metabolism, including miRNA processing. Here, we review the current knowledge about miRNA metabolism and biological functions and their crucial role in ALS pathogenesis with an in-depth analysis on different pathways. A more precise understanding of miRNA involvement in ALS could be useful not only to elucidate their role in the disease etiopathogenesis but also to investigate their potential as disease biomarkers and novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.